YTEN - Yield10 Bioscience Inc Stock Price, Fair Value and News

2.11USD-0.26 (-10.97%)Delayed

Market Summary

USD2.11-0.26

Delayed

-10.97%

YTEN Stock Price

View Fullscreen

YTEN RSI Chart

YTEN Valuation

Market Cap

1.4M

Price/Earnings (Trailing)

-0.1

Price/Sales (Trailing)

4.52

EV/EBITDA

0.02

Price/Free Cashflow

-0.16

YTEN Price/Sales (Trailing)

YTEN Profitability

EBT Margin

-4818.33%

Return on Equity

396.77%

Return on Assets

-309.8%

Free Cashflow Yield

-615.22%

YTEN Fundamentals

YTEN Revenue

Revenue (TTM)

300.0K

Rev. Growth (Yr)

400%

YTEN Earnings

Earnings (TTM)

-13.1M

Earnings Growth (Yr)

34.64%

Earnings Growth (Qtr)

24.31%

Breaking Down YTEN Revenue

Last 7 days

7.9%

Last 30 days

1730.3%

Last 90 days

2316%

Trailing 12 Months

108.3%

How does YTEN drawdown profile look like?

YTEN Financial Health

Current Ratio

0.34

YTEN Investor Care

Shares Dilution (1Y)

203.65%

Diluted EPS (TTM)

-31.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	300.0K	0	0	0
2023	361.0K	258.0K	147.0K	60.0K
2022	567.0K	496.0K	515.0K	450.0K
2021	816.0K	769.0K	657.0K	614.0K
2020	861.0K	764.0K	744.0K	799.0K
2019	620.0K	653.0K	801.0K	806.0K
2018	680.0K	672.0K	525.0K	556.0K
2017	1.3M	1.4M	1.2M	944.0K
2016	1.7M	1.2M	1.3M	1.2M
2015	2.8M	2.9M	2.6M	2.2M
2014	3.1M	2.7M	2.7M	2.8M
2013	3.3M	3.5M	3.5M	3.8M
2012	17.2M	25.3M	33.3M	41.4M
2011	594.0K	676.0K	1.1M	9.2M
2010	0	1.1M	773.7K	448.0K
2009	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Yield10 Bioscience Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	sinskey anthony j	acquired	-	-	20,561	-
Mar 28, 2024	hamilton richard william	acquired	-	-	41,118	-
Mar 28, 2024	van nostrand robert l	acquired	-	-	11,924	-
Feb 15, 2024	peoples oliver p	acquired	60,000	0.3	200,000	president and ceo
Feb 15, 2024	snell kristi	acquired	36,000	0.3	120,000	vp research and cso
Feb 15, 2024	brum lynne h	acquired	30,000	0.3	100,000	vp, planning and corporate com
Feb 15, 2024	haaser charles b	acquired	30,000	0.3	100,000	vp finance and cao
Dec 29, 2023	hamilton richard william	acquired	-	-	16,275	-
Dec 29, 2023	van nostrand robert l	acquired	-	-	18,879	-
Dec 29, 2023	sinskey anthony j	acquired	-	-	16,275	-

Which funds bought or sold YTEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	3,897	3,897	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	351,827	351,827	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	3.44	1,588	4,051	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	6,208	6,208	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-7,856	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-2,424	-	-%
May 14, 2024	Qube Research & Technologies Ltd	new	-	152	152	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-3,000	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	8,749	23,748	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-2,000	-	-%

Are Funds Buying or Selling YTEN?

Are funds buying YTEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own YTEN

No. of Funds

Unveiling Yield10 Bioscience Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Oct 11, 2023	schuler jack w	21.8%	2,835,339	SC 13D
May 26, 2023	schuler jack w	21.7%	1,395,339	SC 13D/A
Apr 08, 2022	hirschman orin	0%	0	SC 13G/A
Feb 11, 2022	hirschman orin	7.15%	349,200	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	0.20%	10,000	SC 13G/A
Jun 09, 2021	morgan stanley	2.0%	96,095	SC 13G/A
Feb 11, 2021	hudson bay capital management lp	6.65%	237,500	SC 13G
Feb 05, 2021	schuler jack w	37.69%	1,735,443	SC 13D/A
Feb 01, 2021	morgan stanley	5.1%	169,627	SC 13G
Jan 19, 2021	lind global macro fund lp	4.5%	150,678	SC 13G/A

Recent SEC filings of Yield10 Bioscience Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 15, 2024	8-K	Current Report
May 09, 2024	RW	RW
May 07, 2024	S-1/A	Initial Public Offering
May 03, 2024	S-1	Initial Public Offering
May 01, 2024	8-K	Current Report
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Yield10 Bioscience Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
CTVA	39.4B	16.8B	5.47%	0.48%	70.46	2.34	-5.10%	-52.75%
CF	13.9B	6.1B	-2.02%	16.01%	9.77	2.29	-41.06%	-59.67%
MOS	9.8B	12.8B	1.09%	-14.45%	12.69	0.77	-32.09%	-72.66%
MID-CAP
FMC	8.0B	4.1B	14.16%	-41.00%	7.11	1.97	-29.94%	54.85%
SMG	3.9B	3.4B	0.78%	-2.24%	-11.14	1.13	-8.26%	43.84%
SMALL-CAP
UAN	903.5M	582.9M	12.18%	0.73%	10.87	1.55	-30.52%	-71.82%
IPI	330.1M	174.0M	29.11%	26.49%	-7.62	1.88	2.45%	-195.60%
AVD	254.7M	589.6M	-19.25%	-46.47%	35.6	0.43	0.81%	-63.10%
CGA	41.4M	-	0.36%	-10.83%	-1.51	0.36	-26.60%	-59.68%
YTEN	1.4M	300.0K	1730.30%	108.28%	-0.1	4.52	-16.90%	6.22%

Yield10 Bioscience Inc News

Latest updates

Yield10 Bioscience Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	300,000	-	-	-	60,000	87,000	111,000	103,000	149,000	152,000	92,000	174,000	196,000	195,000	204,000	221,000	179,000	140,000	224,000	318,000	124,000
Costs and Expenses	-15.6%	2,740,000	3,247,000	3,703,000	3,667,000	3,860,000	3,291,000	3,601,000	3,539,000	3,470,000	3,120,000	3,183,000	3,255,000	2,748,000	2,805,000	2,398,000	2,358,000	2,847,000	2,555,000	2,222,000	2,216,000	2,409,000
S&GA Expenses	6.8%	1,374,000	1,287,000	1,499,000	1,670,000	1,698,000	1,403,000	1,518,000	1,523,000	1,707,000	1,522,000	1,547,000	1,604,000	1,432,000	1,383,000	1,098,000	1,179,000	1,387,000	1,353,000	990,000	1,025,000	1,186,000
EBITDA Margin	80.0%	-47.00	-234	-95.71	-53.59	-37.64	-29.19	-25.13	-23.93	-20.34	-17.53	-15.86	-13.26	-10.93	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	129,000	9,000	9,000	9,000	11,000	6,000	11,000	8,000	30,000	11,000	7,000	8,000	-254,000	-	-	-
Earnings Before Taxes	100.0%	-	-3,266,000	-3,726,000	-3,681,000	-3,782,000	-3,174,000	-3,480,000	-3,434,000	-3,322,000	-2,969,000	-2,392,000	-3,081,000	-2,553,000	-2,612,000	-2,157,000	-1,789,000	-3,592,000	-7,097,000	-1,982,000	-1,871,000	-2,260,000
EBT Margin	80.0%	-48.18	-240	-97.71	-54.72	-38.42	-29.80	-25.64	-24.43	-20.75	-17.91	-16.19	-13.53	-11.17	-	-	-	-	-	-	-	-
Net Income	24.3%	-2,472,000	-3,266,000	-3,726,000	-3,681,000	-3,782,000	-3,303,000	-3,489,000	-3,443,000	-3,331,000	-2,980,000	-2,398,000	-3,092,000	-2,561,000	-2,642,000	-2,168,000	-1,796,000	-3,600,000	-6,843,000	-1,982,000	-1,871,000	-2,260,000
Net Income Margin	81.8%	-43.82	-240	-98.59	-55.25	-38.83	-30.15	-25.71	-24.50	-20.81	-17.97	-16.28	-13.61	-11.23	-	-	-	-	-	-	-	-
Free Cashflow	47.8%	-903,000	-1,731,000	-2,610,000	-3,097,000	-2,676,000	-3,062,000	-2,723,000	-2,557,000	-3,216,000	-2,527,000	-2,003,000	-2,174,000	-2,738,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	8.6%	4,243	3,907	6,042	5,870	5,334	8,085	11,272	14,273	17,104	20,415	22,946	25,210	27,568	14,522	16,646	13,366	15,046	16,718	9,419	11,156	13,095
Current Assets	51.6%	2,123	1,400	3,362	3,025	2,443	5,018	7,895	10,704	13,375	16,624	19,054	21,185	22,530	10,342	12,361	8,990	10,509	11,684	3,499	5,017	6,738
Cash Equivalents	53.9%	1,644	1,068	2,817	2,336	1,809	2,356	4,186	3,444	2,392	5,593	14,882	15,905	18,846	3,687	3,249	3,544	4,549	5,749	3,209	3,584	6,397
Net PPE	-11.1%	487	548	594	663	715	775	840	895	945	890	903	949	968	921	935	978	1,021	1,243	1,247	1,298	1,335
Liabilities	18.2%	7,556	6,390	5,650	5,283	4,191	3,685	4,052	4,002	3,893	4,389	4,458	4,748	4,474	4,990	4,774	4,879	5,717	20,803	6,799	6,702	6,900
Current Liabilities	27.6%	6,210	4,865	3,953	2,470	2,270	1,610	1,826	1,627	1,376	1,733	1,666	1,823	1,421	1,814	1,476	1,462	2,187	2,207	1,754	1,506	1,502
Shareholder's Equity	-33.4%	-3,313	-2,483	392	587	1,143	4,400	7,220	10,271	13,211	16,026	18,488	20,462	23,094	9,532	11,872	8,487	9,329	-	2,620	4,454	6,195
Retained Earnings	-0.6%	-416,624	-414,152	-410,886	-407,160	-403,479	-399,697	-396,394	-392,905	-389,462	-386,131	-383,151	-380,753	-377,661	-375,100	-372,458	-370,290	-368,494	-364,894	-358,051	-356,069	-354,198
Additional Paid-In Capital	0.4%	413,567	411,814	411,406	407,930	404,803	404,277	403,799	403,347	402,817	402,283	401,760	401,319	400,865	384,758	384,465	378,924	377,963	360,926	360,670	360,516	360,383
Shares Outstanding	28.0%	642	501	496	254	212	206	204	204	204	203	203	203	179	-	-	-	-	-	-	-	-
Float	-	-	-	-	9,843	-	-	-	8,868	-	-	-	33,637	-	-	-	9,581	-	-	-	8,012	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	47.2%	-903	-1,711	-2,611	-3,079	-2,667	-3,062	-2,702	-2,538	-3,102	-2,485	-1,992	-2,139	-2,637	-1,989	-2,058	-2,324	-2,288	-3,209	-1,368	-1,781	-2,296
Share Based Compensation	5.2%	403	383	379	394	436	445	447	488	523	500	436	415	324	233	209	160	137	250	131	113	162
Cashflow From Investing	100.0%	-	-20.00	1.00	-18.00	1,982	1,500	3,494	3,616	-88.00	-6,807	1,006	-807	2,030	2,480	-3,589	249	215	-5,749	999	-1,011	2,746
Cashflow From Financing	-	1,211	-	3,092	3,638	141	-	-23.00	-	-14.00	-	-20.00	-	15,766	-62.00	5,350	1,063	928	11,500	-	-18.00	2,597

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

YTEN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 300	$ 60
Expenses:
Research and development	1,366	2,162
General and administrative	1,374	1,698
Total expenses	2,740	3,860
Loss from operations	(2,440)	(3,800)
Other income (expense):
Other income (expense), net	(32)	18
Total other income (expense)	(32)	18
Net loss	$ (2,472)	$ (3,782)
Basic net loss per share (in USD per share)	$ (4.77)	$ (18.16)
Diluted net loss per share (in USD per share)	$ (4.77)	$ (18.16)
Number of shares used in per share calculations:
Basic (in shares)	518,534	208,323
Diluted (in shares)	518,534	208,323
Grant revenue
Revenue:
Revenue	$ 0	$ 60
License revenue
Revenue:
Revenue	$ 300	$ 0

YTEN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 1,597	$ 1,068
Prepaid expenses and other current assets	526	332
Total current assets	2,123	1,400
Restricted cash	47	264
Property and equipment, net	487	548
Right-of-use assets, net	1,529	1,653
Other assets	57	42
Total assets	4,243	3,907
Current Liabilities:
Accounts payable	1,646	1,202
Accrued expenses	1,187	2,010
Deferred revenue	1,700	0
Current portion of lease liabilities	687	669
Convertible note payable, net of issuance costs (Note 8)	990	984
Total current liabilities	6,210	4,865
Lease liabilities, net of current portion	1,346	1,525
Total liabilities	7,556	6,390
Commitments and contingencies (Note 9)
Stockholders’ Deficit:
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock ($0.01 par value per share); 60,000,000 shares authorized at March 31, 2024 and December 31, 2023; $641,744 and $501,357 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	6	5
Additional paid-in capital	413,567	411,929
Accumulated other comprehensive loss	(262)	(265)
Accumulated deficit	(416,624)	(414,152)
Total stockholders’ deficit	(3,313)	(2,483)
Total liabilities and stockholders’ deficit	$ 4,243	$ 3,907

About Yield10 Bioscience Inc

Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds. Its products include Camelina oil for low carbon biofuel feedstock; Omega-3 oils for nutrition; and PHA bioplastics for biodegradable zero waste packaging solutions. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts.

CEO	Dr. Oliver P. Peoples Ph.D.
WEBSITE	yield10bio.com
INDUSTRY	Agriculture
EMPLOYEES	30

Yield10 Bioscience Inc Frequently Asked Questions

What is the ticker symbol for Yield10 Bioscience Inc? What does YTEN stand for in stocks?

YTEN is the stock ticker symbol of Yield10 Bioscience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Yield10 Bioscience Inc (YTEN)?

As of Thu May 16 2024, market cap of Yield10 Bioscience Inc is 1.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of YTEN stock?

You can check YTEN's fair value in chart for subscribers.

What is the fair value of YTEN stock?

You can check YTEN's fair value in chart for subscribers. The fair value of Yield10 Bioscience Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Yield10 Bioscience Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for YTEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Yield10 Bioscience Inc a good stock to buy?

The fair value guage provides a quick view whether YTEN is over valued or under valued. Whether Yield10 Bioscience Inc is cheap or expensive depends on the assumptions which impact Yield10 Bioscience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for YTEN.

What is Yield10 Bioscience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, YTEN's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 5.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. YTEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Yield10 Bioscience Inc's stock?

In the past 10 years, Yield10 Bioscience Inc has provided -0.459 (multiply by 100 for percentage) rate of return.